KLADRİBİN+ DÜŞÜK DOZ SİTARABİN (LD-ARAC) PROTOKOLÜ

Kaynaklar:

1- Kantarjian HM, Thomas XG, Dmoszynska A, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol 2012; 30(21): 2670–7. 

2- Kadia TM, Faderl S, Ravandi F, et al. Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia. Cancer 2015; 121(14): 2375–82. 

3- Spurgeon S, Yu M, Phillips JD, Epner EM. Cladribine: not just another purine analogue? Expert opinion on investigational drugs 2009; 18(8): 1169–81. 

4- Wyczechowska D, Fabianowska-Majewska K. The effects of cladribine and fludarabine on DNA methylation in K562 cells. Biochemical pharmacology 2003; 65(2): 219–25. 

5- Holowiecki J, Grosicki S, Giebel S, et al. Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study. J Clin Oncol 2012; 30(20): 2441–8.

6- Holowiecki J, Grosicki S, Robak T, et al. Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study. Leukemia 2004; 18(5): 989–97. 

7- Gandhi V, Estey E, Keating MJ, Chucrallah A, Plunkett W. Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions. Blood 1996; 87(1): 256–64. 

8- Kornblau SM, Gandhi V, Andreeff HM, et al. Clinical and laboratory studies of 2-chlorodeoxyadenosine +/− cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults. Leukemia 1996; 10(10): 1563–9.

9- Santana VM, Mirro J Jr., Kearns C, Schell MJ, Crom W, Blakley RL. 2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia. J Clin Oncol 1992; 10(3): 364–70.